StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report issued on Friday. The firm issued a sell rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Shares of Navidea Biopharmaceuticals stock opened at $0.00 on Friday. The stock has a fifty day simple moving average of $0.02 and a 200 day simple moving average of $0.04. Navidea Biopharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.15. The company has a market capitalization of $100,084.00, a P/E ratio of -0.02 and a beta of 1.47.
Navidea Biopharmaceuticals Company Profile
Featured Articles
- Five stocks we like better than Navidea Biopharmaceuticals
- How to Use Stock Screeners to Find Stocks
- Survey: Top 175 Fittest Retirement Locations in America
- Options Trading – Understanding Strike Price
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Upcoming IPO Stock Lockup Period, Explained
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.